We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.19%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.78B
AUM Growth
-$1.32B
Cap. Flow
-$329M
Cap. Flow %
-4.22%
Top 10 Hldgs %
29.03%
Holding
186
New
13
Increased
33
Reduced
45
Closed
29

Top Buys

Rank Stock Value
1
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$254M
2
PFE icon
Pfizer
PFE
+$130M
3
CMPX icon
Compass Therapeutics
CMPX
+$71.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$64.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$61.9M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$156M
2
ELV icon
Elevance Health
ELV
+$77.2M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M
4
PGNY icon
Progyny
PGNY
+$71.1M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$68.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.32%
2 Industrials 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
51
Syndax Pharmaceuticals
SNDX
$1.74B
$43.4M 0.56%
1,981,300
+1,790,700
+940% +$33.1M
OSH
52
DELISTED
Oak Street Health, Inc.
OSH
$42.8M 0.55%
1,290,300
-38,000
-3% -$1.44M
XTNT icon
53
Xtant Medical Holdings
XTNT
$59.7M
$40.8M 0.52%
72,873,494
– –
NPCE icon
54
Neuropace
NPCE
$522M
$40.4M 0.52%
4,012,281
– –
LKFT
55
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$39.5M 0.51%
717,257
-6,200
-0.9% -$323K
TELA icon
56
TELA Bio
TELA
$30M
$38.8M 0.5%
3,027,542
– –
VRNA
57
DELISTED
Verona Pharma
VRNA
$38.3M 0.49%
5,694,841
– –
IMA
58
ImageneBio Inc
IMA
$65.5M
$36.8M 0.47%
244,495
– –
SEM
59
DELISTED
Select Medical
SEM
$36.3M 0.47%
2,289,562
-69,600
-3% -$1.19M
IVVD icon
60
Invivyd
IVVD
$175M
$36.2M 0.47%
4,983,500
-400,000
-7% -$10.4M
ORIC icon
61
Oric Pharmaceuticals
ORIC
$1.23B
$34.4M 0.44%
2,337,574
– –
NSTG
62
DELISTED
NanoString Technologies, Inc.
NSTG
$34.1M 0.44%
807,100
+251,100
+45% +$11M
GHRS icon
63
GH Research
GHRS
$1.92B
$33.3M 0.43%
1,428,732
+66
+0% +$1.45K
SRRA
64
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$32.1M 0.41%
1,477,320
– –
CTKB icon
65
Cytek Biosciences
CTKB
$576M
$31.4M 0.4%
1,923,139
– –
IMGN
66
DELISTED
Immunogen Inc
IMGN
$28.7M 0.37%
3,868,786
-11,029,128
-74% -$68.5M
MREO
67
Mereo BioPharma
MREO
$49.4M
– –
-17,264,764
Closed -$34.5M
TERN
68
DELISTED
Terns Pharmaceuticals
TERN
$26.8M 0.34%
3,791,204
– –
PCVX icon
69
Vaxcyte
PCVX
$7.88B
$26.1M 0.34%
1,096,700
+62,035
+6% +$1.44M
ERAS icon
70
Erasca
ERAS
$6.3B
$26M 0.33%
1,667,693
-499,648
-23% -$8.55M
EVH icon
71
Evolent Health
EVH
$421M
$26M 0.33%
938,000
+593,000
+172% +$17M
VECT
72
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$25.6M 0.33%
5,223,804
+100,500
+2% +$495K
VTYX
73
DELISTED
Ventyx Biosciences
VTYX
$25.6M 0.33%
+1,289,280
New +$24.4M
VTGN icon
74
VistaGen Therapeutics
VTGN
$9.55M
$25.2M 0.32%
430,309
– –
THC icon
75
Tenet Healthcare
THC
$22.6B
$24.4M 0.31%
299,000
-12,700
-4% -$928K
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2021 Portfolio in Review

As of Q4 2021, OrbiMed held 186 positions worth $7.78B, down 15% from $9.1B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

OrbiMed withdrew a net $329M in Q4 2021, closing 29 positions and reducing 45 holdings. Its most notable exit was Elevance Health, an estimated $77.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials and Technology.

Against the trend, OrbiMed opened a new position in Theseus Pharmaceuticals, Inc. Common Stock worth $214M.

  • OrbiMed's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 16,838,668 shares worth $214M.
  • OrbiMed added most to Seagen Inc. Common Stock in Q4 2021, an estimated $64.9M increase.
  • OrbiMed's biggest Q4 2021 reduction was Merck, cutting an estimated $156M.
  • OrbiMed fully exited Elevance Health in Q4 2021, selling an estimated $77.2M.
  • OrbiMed's ten largest holdings make up 29% of its $7.78B portfolio in Q4 2021.
  • OrbiMed opened 13 new positions and closed 29 in Q4 2021.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $7.78B.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.